查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1435168

老龄化黄斑部病变市场：按类型、治疗类型、分销管道划分 - 全球预测 2024-2030

Age-related Macular Degeneration Market by Type (Dry Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration), Treatment Type (Drugs, Laser Treatment), Distribution Channel - Global Forecast 2024-2030
出版日期: | 出版商: 360iResearch | 英文 196 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计2023年老龄化黄斑部病变市场规模为111.7亿美元，预计2024年将达到119.2亿美元，2030年将达到181.6亿美元，复合年增长率为7.18%。

老龄化黄斑部病变的全球市场

主要市场统计
基准年[2023] 111.7亿美元
预测年份 [2024] 119.2亿美元
预测年份 [2030] 181.6亿美元
复合年增长率（%） 7.18%
老年黄斑部病变市场-IMG1

FPNV定位矩阵

FPNV定位矩阵对于评估黄斑部病变市场至关重要。我们检视与业务策略和产品满意度相关的关键指标，以对供应商进行全面评估。这种深入的分析使用户能够根据自己的要求做出明智的决策。根据评估，供应商被分为四个成功程度不同的像限：前沿（F）、探路者（P）、利基（N）和重要（V）。

市场占有率分析

市场占有率分析是一种综合工具，可以对老龄化黄斑部病变市场中供应商的现状进行深入而深入的研究。全面比较和分析供应商在整体收益、基本客群和其他关键指标方面的贡献，以便更好地了解公司的绩效及其在争夺市场占有率时面临的挑战。此外，该分析还提供了对该行业竞争特征的宝贵见解，包括在研究基准年观察到的累积、分散主导地位和合併特征等因素。这种详细程度的提高使供应商能够做出更明智的决策并制定有效的策略，从而在市场上获得竞争优势。

该报告对以下几个方面提供了宝贵的见解：

1-市场渗透率：提供有关主要企业所服务的市场的全面资讯。

2-市场开拓：我们深入研究利润丰厚的新兴市场并分析其在成熟细分市场的渗透率。

3- 市场多元化：提供有关新产品发布、开拓地区、最新发展和投资的详细资讯。

4-竞争力评估与资讯：对主要企业的市场占有率、策略、产品、认证、监管状况、专利状况、製造能力等进行全面评估。

5- 产品开发与创新：提供对未来技术、研发活动和突破性产品开发的见解。

本报告解决了以下关键问题：

1-老龄化黄斑部病变市场的市场规模和预测是多少？

2-在老龄化黄斑部病变市场的预测期内，有哪些产品、细分市场、应用和领域需要考虑投资？

3-老龄化黄斑部病变市场的技术趋势和法律规范是什么？

4-老龄化黄斑部病变市场主要供应商的市场占有率是多少？

5-进入老龄化黄斑部病变市场的合适型态和策略手段有哪些？

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 世界各地的老年人口正在增加
      • 雷射治疗和血管生成抑制剂的使用激增
      • 增加眼科疾病诊断设施数量
    • 抑制因素
      • 目前老龄化黄斑部病变的治疗局限性
    • 机会
      • 减少老龄化黄斑部病变影响的新研究工作
      • 介绍基于细胞疗法和组织工程的新型先进治疗方法
    • 任务
      • 熟练的卫生保健工作者数量有限
  • 市场区隔分析
  • 市场趋势分析
  • 高通膨的累积效应
  • 波特五力分析
  • 价值炼和关键路径分析
  • 法律规范

第六章老龄化黄斑部病变市场：依类型

  • 干性老龄化黄斑部病变
  • 湿性老龄化黄斑部病变

第 7 章按治疗类型分類的老龄化黄斑部病变市场

  • 药品
  • 雷射治疗

第八章老龄化黄斑部病变市场：按分销管道

  • 医院药房
  • 网路药房
  • 零售药房

第九章美洲老龄化黄斑部病变市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第十章亚太老龄化黄斑部病变市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第十一章欧洲、中东和非洲老龄化黄斑部病变市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十二章竞争形势

  • FPNV定位矩阵
  • 市场占有率分析：主要企业
  • 主要企业竞争情境分析

第13章竞争产品组合

  • 主要公司简介
    • Alcon Vision LLC
    • Alkahest, Inc.
    • Alkeus Pharmaceuticals, Inc.
    • Allegro Ophthalmics, LLC
    • Amgen Inc.
    • Annexon, Inc.
    • Apellis Pharmaceuticals, Inc.
    • Bayer AG
    • Biogen Inc.
    • Carl Zeiss AG
    • Clearside Biomedical, Inc.
    • Coherus Biosciences, Inc.
    • Graybug Vision, Inc.
    • Gyroscope Therapeutics Limited by Novartis AG
    • Heidelberg Engineering GmbH
    • Ionis Pharmaceuticals, Inc.
    • Janssen Pharmaceuticals, Inc.
    • Kodiak Sciences Inc.
    • Merck & Co., Inc.
    • Nicox SA
    • Regeneron Pharmaceuticals Inc.
    • Santen Pharmaceutical Co., Ltd.
    • Sun Pharmaceutical Industries, Inc.
    • Teva Pharmaceutical Industries Ltd.
    • Viatris Inc.
  • 主要产品系列

第十四章附录

  • 讨论指南
  • 关于许可证和定价
Product Code: MRR-F927BA46235C

[196 Pages Report] The Age-related Macular Degeneration Market size was estimated at USD 11.17 billion in 2023 and expected to reach USD 11.92 billion in 2024, at a CAGR 7.18% to reach USD 18.16 billion by 2030.

Global Age-related Macular Degeneration Market

KEY MARKET STATISTICS
Base Year [2023] USD 11.17 billion
Estimated Year [2024] USD 11.92 billion
Forecast Year [2030] USD 18.16 billion
CAGR (%) 7.18%
Age-related Macular Degeneration Market - IMG1

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Age-related Macular Degeneration Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Age-related Macular Degeneration Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Age-related Macular Degeneration Market, highlighting leading vendors and their innovative profiles. These include Alcon Vision LLC, Alkahest, Inc., Alkeus Pharmaceuticals, Inc., Allegro Ophthalmics, LLC, Amgen Inc., Annexon, Inc., Apellis Pharmaceuticals, Inc., Bayer AG, Biogen Inc., Carl Zeiss AG, Clearside Biomedical, Inc., Coherus Biosciences, Inc., Graybug Vision, Inc., Gyroscope Therapeutics Limited by Novartis AG, Heidelberg Engineering GmbH, Ionis Pharmaceuticals, Inc., Janssen Pharmaceuticals, Inc., Kodiak Sciences Inc., Merck & Co., Inc., Nicox SA, Regeneron Pharmaceuticals Inc., Santen Pharmaceutical Co., Ltd., Sun Pharmaceutical Industries, Inc., Teva Pharmaceutical Industries Ltd., and Viatris Inc..

Market Segmentation & Coverage

This research report categorizes the Age-related Macular Degeneration Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Type
    • Dry Age-Related Macular Degeneration
    • Wet Age-Related Macular Degeneration
  • Treatment Type
    • Drugs
    • Laser Treatment
  • Distribution Channel
    • Hospital Pharmacies
    • Online Pharmacies
    • Retail Pharmacies
  • Region
    • Americas
      • Argentina
      • Brazil
      • Canada
      • Mexico
      • United States
        • California
        • Florida
        • Illinois
        • New York
        • Ohio
        • Pennsylvania
        • Texas
    • Asia-Pacific
      • Australia
      • China
      • India
      • Indonesia
      • Japan
      • Malaysia
      • Philippines
      • Singapore
      • South Korea
      • Taiwan
      • Thailand
      • Vietnam
    • Europe, Middle East & Africa
      • Denmark
      • Egypt
      • Finland
      • France
      • Germany
      • Israel
      • Italy
      • Netherlands
      • Nigeria
      • Norway
      • Poland
      • Qatar
      • Russia
      • Saudi Arabia
      • South Africa
      • Spain
      • Sweden
      • Switzerland
      • Turkey
      • United Arab Emirates
      • United Kingdom

The report offers valuable insights on the following aspects:

1. Market Penetration: It presents comprehensive information on the market provided by key players.

2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.

3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.

4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.

5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

1. What is the market size and forecast of the Age-related Macular Degeneration Market?

2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Age-related Macular Degeneration Market?

3. What are the technology trends and regulatory frameworks in the Age-related Macular Degeneration Market?

4. What is the market share of the leading vendors in the Age-related Macular Degeneration Market?

5. Which modes and strategic moves are suitable for entering the Age-related Macular Degeneration Market?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Limitations
  • 1.7. Assumptions
  • 1.8. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

  • 4.1. Introduction
  • 4.2. Age-related Macular Degeneration Market, by Region

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Growing number of geriatric population across the world
      • 5.1.1.2. Surging use of laser therapy and anti-angiogenesis drugs
      • 5.1.1.3. Increasing diagnostics facilities for eye problems
    • 5.1.2. Restraints
      • 5.1.2.1. Current treatment limitations in age-related macular degeneration
    • 5.1.3. Opportunities
      • 5.1.3.1. Emerging research activities for reducing impact of age-related macular degeneration
      • 5.1.3.2. Introduction of novel and advanced treatments based on cell therapy and tissue engineering
    • 5.1.4. Challenges
      • 5.1.4.1. Limited skilled healthcare professionals
  • 5.2. Market Segmentation Analysis
  • 5.3. Market Trend Analysis
  • 5.4. Cumulative Impact of High Inflation
  • 5.5. Porter's Five Forces Analysis
    • 5.5.1. Threat of New Entrants
    • 5.5.2. Threat of Substitutes
    • 5.5.3. Bargaining Power of Customers
    • 5.5.4. Bargaining Power of Suppliers
    • 5.5.5. Industry Rivalry
  • 5.6. Value Chain & Critical Path Analysis
  • 5.7. Regulatory Framework

6. Age-related Macular Degeneration Market, by Type

  • 6.1. Introduction
  • 6.2. Dry Age-Related Macular Degeneration
  • 6.3. Wet Age-Related Macular Degeneration

7. Age-related Macular Degeneration Market, by Treatment Type

  • 7.1. Introduction
  • 7.2. Drugs
  • 7.3. Laser Treatment

8. Age-related Macular Degeneration Market, by Distribution Channel

  • 8.1. Introduction
  • 8.2. Hospital Pharmacies
  • 8.3. Online Pharmacies
  • 8.4. Retail Pharmacies

9. Americas Age-related Macular Degeneration Market

  • 9.1. Introduction
  • 9.2. Argentina
  • 9.3. Brazil
  • 9.4. Canada
  • 9.5. Mexico
  • 9.6. United States

10. Asia-Pacific Age-related Macular Degeneration Market

  • 10.1. Introduction
  • 10.2. Australia
  • 10.3. China
  • 10.4. India
  • 10.5. Indonesia
  • 10.6. Japan
  • 10.7. Malaysia
  • 10.8. Philippines
  • 10.9. Singapore
  • 10.10. South Korea
  • 10.11. Taiwan
  • 10.12. Thailand
  • 10.13. Vietnam

11. Europe, Middle East & Africa Age-related Macular Degeneration Market

  • 11.1. Introduction
  • 11.2. Denmark
  • 11.3. Egypt
  • 11.4. Finland
  • 11.5. France
  • 11.6. Germany
  • 11.7. Israel
  • 11.8. Italy
  • 11.9. Netherlands
  • 11.10. Nigeria
  • 11.11. Norway
  • 11.12. Poland
  • 11.13. Qatar
  • 11.14. Russia
  • 11.15. Saudi Arabia
  • 11.16. South Africa
  • 11.17. Spain
  • 11.18. Sweden
  • 11.19. Switzerland
  • 11.20. Turkey
  • 11.21. United Arab Emirates
  • 11.22. United Kingdom

12. Competitive Landscape

  • 12.1. FPNV Positioning Matrix
  • 12.2. Market Share Analysis, By Key Player
  • 12.3. Competitive Scenario Analysis, By Key Player

13. Competitive Portfolio

  • 13.1. Key Company Profiles
    • 13.1.1. Alcon Vision LLC
    • 13.1.2. Alkahest, Inc.
    • 13.1.3. Alkeus Pharmaceuticals, Inc.
    • 13.1.4. Allegro Ophthalmics, LLC
    • 13.1.5. Amgen Inc.
    • 13.1.6. Annexon, Inc.
    • 13.1.7. Apellis Pharmaceuticals, Inc.
    • 13.1.8. Bayer AG
    • 13.1.9. Biogen Inc.
    • 13.1.10. Carl Zeiss AG
    • 13.1.11. Clearside Biomedical, Inc.
    • 13.1.12. Coherus Biosciences, Inc.
    • 13.1.13. Graybug Vision, Inc.
    • 13.1.14. Gyroscope Therapeutics Limited by Novartis AG
    • 13.1.15. Heidelberg Engineering GmbH
    • 13.1.16. Ionis Pharmaceuticals, Inc.
    • 13.1.17. Janssen Pharmaceuticals, Inc.
    • 13.1.18. Kodiak Sciences Inc.
    • 13.1.19. Merck & Co., Inc.
    • 13.1.20. Nicox SA
    • 13.1.21. Regeneron Pharmaceuticals Inc.
    • 13.1.22. Santen Pharmaceutical Co., Ltd.
    • 13.1.23. Sun Pharmaceutical Industries, Inc.
    • 13.1.24. Teva Pharmaceutical Industries Ltd.
    • 13.1.25. Viatris Inc.
  • 13.2. Key Product Portfolio

14. Appendix

  • 14.1. Discussion Guide
  • 14.2. License & Pricing

LIST OF FIGURES

  • FIGURE 1. AGE-RELATED MACULAR DEGENERATION MARKET RESEARCH PROCESS
  • FIGURE 2. AGE-RELATED MACULAR DEGENERATION MARKET SIZE, 2023 VS 2030
  • FIGURE 3. AGE-RELATED MACULAR DEGENERATION MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY REGION, 2023 VS 2030 (%)
  • FIGURE 5. AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. AGE-RELATED MACULAR DEGENERATION MARKET DYNAMICS
  • FIGURE 7. AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
  • FIGURE 8. AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 9. AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TREATMENT TYPE, 2023 VS 2030 (%)
  • FIGURE 10. AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TREATMENT TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 11. AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2030 (%)
  • FIGURE 12. AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 13. AMERICAS AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 14. AMERICAS AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 15. UNITED STATES AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 16. UNITED STATES AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 17. ASIA-PACIFIC AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 18. ASIA-PACIFIC AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 19. EUROPE, MIDDLE EAST & AFRICA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 20. EUROPE, MIDDLE EAST & AFRICA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 21. AGE-RELATED MACULAR DEGENERATION MARKET, FPNV POSITIONING MATRIX, 2023
  • FIGURE 22. AGE-RELATED MACULAR DEGENERATION MARKET SHARE, BY KEY PLAYER, 2023

LIST OF TABLES

  • TABLE 1. AGE-RELATED MACULAR DEGENERATION MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. AGE-RELATED MACULAR DEGENERATION MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 6. AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DRY AGE-RELATED MACULAR DEGENERATION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 7. AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY WET AGE-RELATED MACULAR DEGENERATION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 8. AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 9. AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DRUGS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY LASER TREATMENT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 12. AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. AMERICAS AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 16. AMERICAS AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 17. AMERICAS AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 18. AMERICAS AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 19. ARGENTINA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 20. ARGENTINA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 21. ARGENTINA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 22. BRAZIL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 23. BRAZIL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 24. BRAZIL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 25. CANADA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 26. CANADA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 27. CANADA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 28. MEXICO AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 29. MEXICO AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 30. MEXICO AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 31. UNITED STATES AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 32. UNITED STATES AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 33. UNITED STATES AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 34. UNITED STATES AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 35. ASIA-PACIFIC AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 36. ASIA-PACIFIC AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 37. ASIA-PACIFIC AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 38. ASIA-PACIFIC AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 39. AUSTRALIA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 40. AUSTRALIA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 41. AUSTRALIA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 42. CHINA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 43. CHINA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 44. CHINA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 45. INDIA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 46. INDIA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 47. INDIA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 48. INDONESIA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 49. INDONESIA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 50. INDONESIA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 51. JAPAN AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 52. JAPAN AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 53. JAPAN AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 54. MALAYSIA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 55. MALAYSIA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 56. MALAYSIA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 57. PHILIPPINES AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 58. PHILIPPINES AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 59. PHILIPPINES AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 60. SINGAPORE AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 61. SINGAPORE AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 62. SINGAPORE AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 63. SOUTH KOREA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 64. SOUTH KOREA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 65. SOUTH KOREA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 66. TAIWAN AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 67. TAIWAN AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 68. TAIWAN AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 69. THAILAND AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 70. THAILAND AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 71. THAILAND AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 72. VIETNAM AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 73. VIETNAM AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 74. VIETNAM AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 75. EUROPE, MIDDLE EAST & AFRICA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 76. EUROPE, MIDDLE EAST & AFRICA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 77. EUROPE, MIDDLE EAST & AFRICA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 78. EUROPE, MIDDLE EAST & AFRICA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 79. DENMARK AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 80. DENMARK AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 81. DENMARK AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 82. EGYPT AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 83. EGYPT AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 84. EGYPT AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 85. FINLAND AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 86. FINLAND AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 87. FINLAND AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 88. FRANCE AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 89. FRANCE AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 90. FRANCE AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 91. GERMANY AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 92. GERMANY AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 93. GERMANY AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 94. ISRAEL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 95. ISRAEL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 96. ISRAEL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 97. ITALY AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 98. ITALY AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 99. ITALY AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 100. NETHERLANDS AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 101. NETHERLANDS AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 102. NETHERLANDS AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 103. NIGERIA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 104. NIGERIA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 105. NIGERIA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 106. NORWAY AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 107. NORWAY AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 108. NORWAY AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 109. POLAND AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 110. POLAND AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 111. POLAND AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 112. QATAR AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 113. QATAR AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 114. QATAR AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 115. RUSSIA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 116. RUSSIA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 117. RUSSIA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 118. SAUDI ARABIA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 119. SAUDI ARABIA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 120. SAUDI ARABIA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 121. SOUTH AFRICA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 122. SOUTH AFRICA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 123. SOUTH AFRICA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 124. SPAIN AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 125. SPAIN AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 126. SPAIN AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 127. SWEDEN AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 128. SWEDEN AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 129. SWEDEN AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 130. SWITZERLAND AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 131. SWITZERLAND AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 132. SWITZERLAND AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 133. TURKEY AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 134. TURKEY AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 135. TURKEY AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 136. UNITED ARAB EMIRATES AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 137. UNITED ARAB EMIRATES AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 138. UNITED ARAB EMIRATES AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 139. UNITED KINGDOM AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 140. UNITED KINGDOM AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 141. UNITED KINGDOM AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 142. AGE-RELATED MACULAR DEGENERATION MARKET, FPNV POSITIONING MATRIX, 2023
  • TABLE 143. AGE-RELATED MACULAR DEGENERATION MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 144. AGE-RELATED MACULAR DEGENERATION MARKET LICENSE & PRICING